These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31446298)

  • 1. Part 2: Physicochemical characterization of bevacizumab in 2 mg/mL antibody solutions as used in human i.v. administration: Comparison of originator with a biosimilar candidate.
    Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
    J Pharm Biomed Anal; 2019 Nov; 176():112802. PubMed ID: 31446298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Part 1: Physicochemical characterization of bevacizumab in undiluted 25 mg/mL drug product solutions: Comparison of originator with a biosimilar candidate.
    Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
    J Pharm Biomed Anal; 2019 Oct; 175():112742. PubMed ID: 31344647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demonstrating analytical similarity of a biosimilar HLX04 to bevacizumab with a panel of state-of-the-art methods and tiering of quality attributes.
    Zhang L; Yu L; Xu Y; Qin P; Shen P; Liu K; Fei M; Wang H; Cao Y; Lu L; Gao W; Zhang Z
    Anal Bioanal Chem; 2023 Jul; 415(17):3341-3362. PubMed ID: 37162525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid characterization of structural and functional similarity for a candidate bevacizumab (Avastin) biosimilar using a multipronged mass-spectrometry-based approach.
    Brown KA; Rajendran S; Dowd J; Wilson DJ
    Drug Test Anal; 2019 Aug; 11(8):1207-1217. PubMed ID: 31041833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
    Seo N; Polozova A; Zhang M; Yates Z; Cao S; Li H; Kuhns S; Maher G; McBride HJ; Liu J
    MAbs; 2018; 10(4):678-691. PubMed ID: 29553864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of infliximab solutions in different temperature and dilution conditions.
    Tokhadze N; Chennell P; Le Basle Y; Sautou V
    J Pharm Biomed Anal; 2018 Feb; 150():386-395. PubMed ID: 29287266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of bevacizumab by dynamic light scattering while maintaining its native structure.
    Akbas S; Sahin A; Calis S; Oncel H; Capan Y
    Pharmazie; 2018 Jul; 73(7):369-374. PubMed ID: 30001769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars.
    Kang J; Halseth T; Vallejo D; Najafabadi ZI; Sen KI; Ford M; Ruotolo BT; Schwendeman A
    Anal Bioanal Chem; 2020 Jan; 412(3):763-775. PubMed ID: 31853605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
    Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
    BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev
    Weiser S; Burns C; Zartler ER
    J Oncol Pharm Pract; 2023 Jul; 29(5):1032-1043. PubMed ID: 35312402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LC-MS based case-by-case analysis of the impact of acidic and basic charge variants of bevacizumab on stability and biological activity.
    Singh SK; Kumar D; Malani H; Rathore AS
    Sci Rep; 2021 Jan; 11(1):2487. PubMed ID: 33514790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical Similarity of a Proposed Biosimilar BVZ-BC to Bevacizumab.
    Yu C; Zhang F; Xu G; Wu G; Wang W; Liu C; Fu Z; Li M; Guo S; Yu X; Wang L
    Anal Chem; 2020 Feb; 92(4):3161-3170. PubMed ID: 31983199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
    Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
    Biologicals; 2021 Sep; 73():41-56. PubMed ID: 34593306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of aggregates analysis method in analytical similarity assessment of HLX04 vs Avastin®.
    Fei M; Zhang Q; Zhang L; Zhu X; Du C; Zhang Z
    J Pharm Biomed Anal; 2023 Jan; 223():115121. PubMed ID: 36308924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of originator and biosimilar monoclonal antibodies using HRMS, Fc affinity chromatography, and 2D-HPLC.
    Reinders LMH; Klassen MD; Teutenberg T; Jaeger M; Schmidt TC
    Anal Bioanal Chem; 2022 Sep; 414(23):6761-6769. PubMed ID: 35895102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
    Ruppen I; Beydon ME; Solís C; Sacristán D; Vandenheede I; Ortiz A; Sandra K; Adhikary L
    Biologicals; 2022 Jun; 77():1-15. PubMed ID: 35667958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
    Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
    BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects.
    Hettema W; Wynne C; Lang B; Altendorfer M; Czeloth N; Lohmann R; Athalye S; Schliephake D
    Expert Opin Investig Drugs; 2017 Aug; 26(8):889-896. PubMed ID: 28651442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
    Park D; Kim J; Yun J; Park SJ
    Adv Ther; 2020 Oct; 37(10):4308-4324. PubMed ID: 32816233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®.
    Xu Y; Xie L; Zhang E; Gao W; Wang L; Cao Y; Xie MH; Jiang W; Liu S
    MAbs; 2019 Apr; 11(3):606-620. PubMed ID: 30794092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.